KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2021 - 2023)

Ginkgo Bioworks Holdings (DNA) has disclosed Long-Term Investments for 3 consecutive years, with $85.0 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Long-Term Investments changed N/A year-over-year to $85.0 million, compared with a TTM value of $85.0 million through Sep 2023, changed N/A, and an annual FY2022 reading of $1.5 million, down 88.31% over the prior year.
  • Long-Term Investments was $85.0 million for Q3 2023 at Ginkgo Bioworks Holdings, up from $1.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.7 billion in Q2 2021 and bottomed at $1.1 million in Q2 2023.
  • Average Long-Term Investments over 3 years is $243.0 million, with a median of $12.5 million recorded in 2021.
  • Peak annual rise in Long-Term Investments hit 88.31% in 2022, while the deepest fall reached 88.31% in 2022.
  • Year by year, Long-Term Investments stood at $13.2 million in 2021, then crashed by 88.31% to $1.5 million in 2022, then surged by 5406.8% to $85.0 million in 2023.
  • Business Quant data shows Long-Term Investments for DNA at $85.0 million in Q3 2023, $1.1 million in Q2 2023, and $1.2 million in Q1 2023.